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• PCOS is the most common condition
1,
2
affecting women of reproductive age .
• PCOS is a multifactorial condition,
affecting reproductive, metabolic, and
1,
2,
3,
4
psychological aspects of health
.
• Diagnosis of PCOS is often difficult and
often result in diagnosis delays; 70% of
women with PCOS are thought to be
1,
2,
3
undiagnosed
.
• Many women who do receive a diagnosis
of PCOS feel unsatisfied with their
3,
7
diagnosis experience and education .
• Early diagnosis with a thorough and
comprehensive review of the patient is
essential for mitigating many of the
4,
5
comorbidities associated with PCOS .
• It is thought that metabolic disturbances,
primarily insulin resistance and
compensatory hyperinsulinemia, play a
key role in the pathogenesis and
4,
6
progression of PCOS .
• Development of a safe empiric treatment
for suspected PCOS could be very
beneficial.

Understand MYO/DCI as a potential treatment
for PCOS.
- How the supplement works
- Why women may choose to use it
- What to educate PCOS patients about
regarding the use of MYO/DCI

• PCOS is a common condition with a
variety of symptoms, low rates of
diagnosis, and low satisfaction from health
care providers by women who are
diagnosed.
• MYO/DCI inositols are supplements that
are available over the counter and have
been purchased by many women looking
for an alternative way of treating their
symptoms.
• The use of this supplement is promising but
unfortunately remains disorganized and
ultimately experimental for now.

• Inositols are organic chemicals mainly
found in muscle cells, Myo-inositol (MYO)
and D-chiro-inositol (DCI) are the most
8,
9
common isomers of inositol .
• Inositols can be produced by our bodies,
8,
chiefly from the kidneys, liver, and brain
6. However, the consumption of
exogenous MYO through dietary intake
13
(fruit, beans, corn and nuts ) is still
necessary, especially if individuals are not
8,
6
producing enough MYO on their own .
• MYO/DCI supplements are easily
accessible, relatively inexpensive, and
already popular among the public.

Recommendations :

•
•

•

•

Given the dissatisfaction with treatment and
education in relation to women receiving a
Inositols :
PCOS
diagnosis,
it
would
be
extremely
MYO and DCI work in combination in the
beneficial
to
direct
patients
to
further
body to increase insulin sensitivity via second
educational
resources.
6,
8,
9
messenger systems in the cell membrane
.
Reproductive: MYO may aid in fertility
treatment, and MYO/DCI with dietary
If patients are already using MYO/DCI as a
changes may restore menstrual cycles in
supplement for their PCOS, most evidence
13,
14
patients with PCOS
.
points to a dose of 2–4 g/day, with a ratio of
8,
9,
12
Metabolic: MYO may have a similar effect on
40 MYO to 1 DCI
.
metabolic profile as metformin and may be
References:
particularly beneficial in reducing
10
hyperandrogenism in patients with PCOS .
Psychological: It is unclear how MYO/DCI
affects psychological health in PCOS patients.

• Further confirmatory research is needed and
must utilize: larger sample sizes, longer followup periods, clear randomization/blinding
procedures, mitigation of biases, and clear
outcome measures including reproductive,
metabolic, and psychological aspects of
patients with PCOS, as well as side effects of
MYO/DCI.
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